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SYSTEMATIC REVIEW RELIABILITY: EFFICACY OF TWO INDEPENDENT
REVIEWERS AND TWO–STEP REVIEWS
Pietri G, Muston D
Heron Evidence Development Ltd, Stopsley, Luton, UK
OBJECTIVES: In a systematic review of literature, reviewing papers twice by two
reviewers improves the likelihood of correctly including/excluding citations. Also, 
reviewing ﬁ rst the abstract then the full text allows the reviewer to have had more
exposure to the literature, and thus to be more accurate in his decision. A statistical 
model was ﬁ tted and paired t-tests were performed to determine between-reviewer 
and between-review reliability and variation. METHODS: Inclusion/exclusion deci-
sions made by two reviewers at the abstract and the full-text reviews of six recently 
conducted systematic reviews (one economic and ﬁ ve clinical) were analysed and 
compared to the ﬁ nal inclusion/exclusion decision. For both reviewers, sensitivity (the
proportion of correctly included citations) and speciﬁ city (the proportion of correctly 
excluded citations) were modelled using bayesian Poisson regression. Paired t-tests
were performed to evaluate the improvements of sensitivity and speciﬁ city between 
the abstract and the full-text reviews. RESULTS: The sensitivity of reviewer two was
signiﬁ cantly higher in one out of six systematic reviews at abstract review, and in
another one at full-text review. Reviewer two’s speciﬁ city was also signiﬁ cantly higher 
in three systematic reviews at abstract review, and in one systematic review at full-text 
review. Reviewers were on average 89.6% sensitive and 95.7% speciﬁ c at including
or excluding publications at abstract review. At full-text review, the average sensitivity 
increased signiﬁ cantly (97.1%, p  0.006) whereas the speciﬁ city remained similar
(95.9%, p  0.81). CONCLUSIONS: While ﬁ rst and second reviewers tend to have
similar sensitivity in including citations at abstract review, reviewer two tends to be 
more accurate at excluding citations, thus increasing the likelihood of correctly exclud-
ing citations. At full-text review, sensitivity and speciﬁ city tend to be similar between
the two reviewers, but sensitivity increases signiﬁ cantly compared to abstract review. 
This shows that the full-text review provides further conﬁ rmation that the included 
citations are indeed relevant.
PMC9
SIGNIFICANCE OF INCORPORATING COMMUNITY–BASED DATA OF A
TARGET POPULATION INTO PHARMACOECONOMIC MODELS
Farahani P
Berkshire Medical Center, University of Massachusetts Medical School, Pittsﬁ eld, MA, USA
Community-based aspects of therapeutic can inﬂ uence the outcomes of pharmacoeco-
nomic evaluations. OBJECTIVES: To evaluate the effect of incorporating data from 
RCTs versus data from community clinical practices on the results of an economic
model of statins. METHODS: The beneﬁ t of reducing LDL-C was incorporated into 
a model to calculate reduction in cardiovascular events and resulted economic out-
comes. Data for LDL-C reduction from a head-to-head RCT [Am Heart J 
2002;144:1044–51] were obtained for rosuvastatin (starting 5 mg) versus atorvastatin
(starting 10 mg) with up-titration doses. A distribution of cardiovascular risk for users
[N  100,000, duration 5 years] in Canadian population [Clin Invest Med 2007;30:
E63-E69] was assumed. Then, to illustrate the signiﬁ cance of the population level data, 
the data from the Canadian community-based clinical practice settings was removed
from the model and the original RCT probability distribution for cardiovascular risk
strata was applied into the model. RESULTS: Using community-based data modelling 
rosuvastatin and atorvastatin can prevent 9505 and 8702 cardiovascular events (non-
fatal MI and stroke). Reduction in non-fatal MI and stroke can be translated to 
$252,300,392 (CDN), and $230,980,624 direct cost savings, respectively. Incorporat-
ing the RCT cardiovascular risk distribution, rosuvastatin and atorvastatin can 
prevent 7129 and 6712 cardiovascular events. This could lead to $180,214,565 and 
$178,152,982 direct cost savings for the Canadian health care system (adherence to 
therapy was assumed to be at the level of RCT). CONCLUSIONS: The distribution 
of cardiovascular risk was dissimilar between the RCT and the Canadian community-
based data. The proportion of low risk patients enrolled in the RCT was signiﬁ cantly
higher in comparison with the proportion of low risk patients on statin therapy in the 
Canadian community. Therefore, in this case the magnitude of cost savings would
considerably be reduced if the RCT data were incorporated into the model instead of 
the community-based data.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Cost Methods
PMC10
COMPARISON BETWEEN PROPENSITY SCORE AND TRADITIONAL 
COVARIATE ADJUSTMENT WITH LOGISTIC REGRESSION MODELS IN 
ESTIMATING THE AVERAGE TREATMENT EFFECTS (ATES): RESULTS
FROM MONTE CARLO SIMULATIONS
Le QA, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Several recent systematic reviews of published studies in clinical
research using both traditional covariate adjustment regression and propensity score 
(PS) methodology to control for confounding reported that both methods produced 
similar estimating results. In this study, we used Monte Carlo simulations to evaluate
performance of different models derived from the two methods. METHODS: Sixteen
dichotomous variables (X1 – X16) with different levels of association between treat-
ment and outcome were randomly and simultaneously generated from the independent 
Bernoulli distribution with a probability of 0.5. Twelve variables (X1, X2, X3, X5, 
X6, X7, X9, X10, X11, X13, X14, and X15) are associated with treatment assign-
ment; while (X1 – X12) are associated with the outcome; and X16 is neither associated 
with treatment assignment nor outcome. We investigated six models, of which two
models using traditional covariate adjustment with logistic regression (LR), one 
model without adjustment for confounders, and three models using PS as followed: 
(1) model 1: adjusted for 16 variables; (2) model 2: adjusted for 12 variables associated
with outcome; (3) model 3: no adjustment for confounders; (4) model 4: adjusted 
for the PS; (5) model 5: stratiﬁ ed on 5 quintiles of the PS; and (6) model 6: 4-digit 
match on the PS. RESULTS: The conventional covariate adjustment with LR (model
1 and 2) consistently and unbiasedly estimated the speciﬁ ed ATEs. Without covariate 
adjustment, model 3 produced biased estimations. Among all three PS models (models
4, 5, and 6), only model 6 resulted in unbiased estimation of the speciﬁ ed
ATEs. However, compared with traditional covariate adjustment with LR, model 6, 
though produced unbiased estimates, had larger variances. CONCLUSIONS: For 
dichotomous confounders, adjustment and stratiﬁ cation on the quintiles of the PS, 
though widely used in clinical research, produce biased estimations; while conven-
tional covariate adjustment with LR resulted in unbiased estimations with small 
variances.
PMC11
GROWTH, CHARACTERISTICS AND QUALITY OF THE COST–UTILITY
ANALYSIS LITERATURE THROUGH 2006
Greenberg D1, Fang C1, Cohen JT1, Eldar-Lissai A2, Neumann PJ1
1Tufts-New England Medical Center, Boston, MA, USA, 2University of Rochester, Rochester, 
NY, USA
OBJECTIVES: To describe the growth over time and methodological quality of cost-
utility analyses (CUAs) published in the peer-reviewed literature through 2006.
METHODS: This study updates and expands our previous work, which examined 
CUAs through 2003 (n  795). We systematically searched the English-language litera-
ture for original CUAs published through 2006 using Medline and other databases.
Two trained readers independently audited each study and collected data on a wide
variety of elements related to study origin, methods, and reporting of results. 
RESULTS: We identiﬁ ed 1431 original CUAs (currently included in the Tufts Medical 
Center Cost-Effectiveness Analysis Registry, www.cearegistry.org). The more than 200 
CUAs published annually from 2004 to 2006 nearly doubled the size of the CUA lit-
erature. Most analyses pertain to the U.S. (51%), followed by the U.K. (16%), and
Canada (7%). CUAs cover a wide range of disease areas, including cardiovascular 
diseases (15%), infectious diseases (14%), and cancer (13%), and examine interven-
tions for tertiary care (62%), secondary prevention (23%), and primary prevention 
(15%). Although most studies adhere to guidelines for conducting and reporting CUA 
results, their average quality (4.2 o 1.1 on a 1–7 Likert scale) did not change substan-
tially over time. Study quality was higher for CUAs published in experienced journals 
(publishing a total of q10 CUAs); (n  31 journals), vs. other (n  390 journals); (4.5 
o 1.1 vs. 3.9 o 1.1, respectively; p  0.0001), for CUAs evaluating pharmaceuticals 
vs. other interventions (4.3 o 1.0 vs. 4.1 o 1.2, respectively; p  0.0001), and for CUAs
supported by a government organization vs. other sponsors (4.4 o 1.0 vs. 4.1 o 1.2, 
respectively; p  0.0001). CONCLUSIONS: The rapid growth in published CUAs
demonstrates the increased role these analyses play in informing resource allocation 
decisions. Journals should conduct more rigorous reviews and assure adherence to
guidelines for conducting and reporting CUA results.
PMC12
VALIDATION OF HEALTH CARE RESOURCE USE
QUESTIONNAIRES IN MEXICO
Tenorio C1, Vargas J2, Ivanova S3, Martínez-Fonseca J3, Paladio Á3, Mould–Quevedo J4
1Instituto Nacional de Cancerología, Mexico, DF, Mexico, 2Econopharma Consulting SA de
CV, Mexico, DF, Mexico, 3Econopharma Consulting SA de CV, Mexico City, Mexico, 4Pﬁ zer 
Mexico, Mexico City, Mexico
OBJECTIVES: Current Mexican health care resource-use questionnaires are subjective 
and not validated through a scientiﬁ c technique. This generates heterogeneity in costs
obtained from several economic evaluations(EE), uneasy to compare methodologically 
and useless to include in future EE alongside clinical trials. The objective of this study 
was to develop and validate three instruments to assess resource utilization from the
societal perspective. METHODS: Three speciﬁ c instruments were constructed for 
patients with cardiovascular diseases (hypertension and acute myocardial infarction); 
oncological (breast, renal and lung cancer) and HIV/AIDS with the aid of a special
Mexican consensus. Instruments were subdivided into two sections: recover medical 
data from hospital records and a survey with patients. The latter was applied to adult 
Mexican patients from the Social Security Mexican Institute(IMSS) between June and
October 2008. Instruments include ﬁ ve dimensions:(diagnostic, treatment and medical 
follow-up, support services, clinical data and epidemiological data) and pretend to be 
helpful to obtain direct costs (data collected from hospital records); and indirect and 
out-of-pocket expenses (data collected from the patient). Sample size estimate used
epidemiological Mexican data and statistical tests were performed to demonstrated
internal consistency reliability (Cronbach’s alpha), interclass correlation coefﬁ cient,
component analysis (parametric bootstrapping) and construct validity was also evalu-
ated. RESULTS: A total of 213 patients were included in the study (31.9% cardiovas-
cular, 30.0% oncological; 38.1% HIV/AIDS). Mean age of participants was 54.9 o
9.08 years; 49.3% were female. Internal consistency was found in all questionnaires:
Cronbach’s alpha reported range for cardiovascular patients from 0.73–0.78; cancer 
patients 0.67–0.80, and HIV/AIDS patients from 0.82–0.87. Higher internal consis-
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tency was observed in the out-of-pocket questionnaire(p  0.05). Component analysis 
showed a few epidemiological variables are responsible for 80% of instrument’s vari-
ability. CONCLUSIONS: Validated resource-use questionnaires are needed to homog-
enize costs and EE in developing countries. These validated questionnaires in Mexican 
population could be used by authorities to enhance cost-containment policies.
PMC13
A QALY ALTERNATIVE FOR COST–EFFECTIVENESS ANALYSIS
IN HEALTH CARE
Gandjour A
Rice University, Houston, TX, USA
The cost-effectiveness of health care interventions is often evaluated using quality-
adjusted life years (QALYs) as a measure of outcome. However, QALYs are valid only
under several restrictive assumptions. Furthermore, QALYs are ethically controversial,
as they receive their strongest support from utilitarian theory, which is often consid-
ered an unacceptable ethical theory. The purpose of this work is to present a non-
utilitarian approach to cost-effectiveness analysis, which avoids calculating QALYs, 
but still is able to aggregate and compare different clinical outcomes. By capturing 
beneﬁ ts in terms of adverse events (AEs) avoided, the approach is based on one of the 
fundamental metrics of clinical epidemiology and thus moves the assessment of cost-
effectiveness closer to that of clinical outcomes in clinical trials. Furthermore, it 
directly incorporates the two most important ethical values with regard to setting 
priorities in health care, ie, a concern for health gain as well as for health without
treatment. The approach aggregates the different types of AEs avoided, by introducing
weights that reﬂ ect their value. In order to project weights on an interval scale, ranking
data, the time trade-off, or the standard gamble method can be used.
PMC14
DETERMINING COSTS OF CONCOMITANT MEDICATIONS
IN RANDOMIZED CLINICAL TRIALS: A CASE STUDY
Han L1, de Moor C2, Whiteley M2, McMillan C1, Payne J1, Naik J1, Kelly S1
1PPD Inc, Wilmington, NC, USA, 2PPD Inc, Morrisville, NC, USA
OBJECTIVES: Determining costs of concomitant medications (CONMEDs) is a chal-
lenging but critical component of cost-effectiveness analysis. In clinical trials,
CONMEDs are typically recorded using broad medication terms, with approximate 
costs linked to the entire category. In a recent phase III oncology clinical trial, we 
determined costs with an alternative approach based on the individual CONMEDs 
used by patients, using a combination of WHO preferred medication term codings, the 
NDC-HCPCS Crosswalk (CW), and Payment Allowance Limits (PAL) for Medicare
Drugs Part. METHODS: The CONMED database was obtained from the clinical trial, 
and the CW and the PAL were obtained from CMS. Preferred medication terms of 
individual CONMEDs were coded according to the WHODrug version 2003 Q2 dic-
tionary. The CW was used to map preferred medication terms to appropriate HCPCS
codes, and the PAL was used to determine unit costs of the HCPCS coded medications. 
For medications with multiple HCPCs codes, the average payment limit per dosage unit
was assigned. Total CONMED costs were computed by adding all cost information. 
RESULTS: The CONMED database comprised approximately 400 patients and 3,588
CONMED records. There were 562 unique HCPCS codes and 497 unique preferred
medication terms in the CW and the PAL. In addition, there were 519 unique combina-
tions of preferred medication terms and dose units, of which 78% (407/519) had mul-
tiple NDC codes. However, only 17% (70/407) of these had different unit payment
limits across products within the combination. In these cases the average cost was used. 
Overall we were able to assign costs to 22% (780/3588) of CONMED records, consis-
tent with the proportion of CONMEDs covered by Medicare. CONCLUSIONS: From 
third party payer perspective, this micro-costing method for CONMEDs was a feasible 
approach to pharmacoeconomic assessment with a clinical trial.
PMC15
EVALUATING AN ONLINE FREEWARE CALCULATOR FOR A
COST EFFECTIVENESS MODEL TO ASSESS THE IMPACT OF
MEDICATION COMPLIANCE
McGhan WF, Willey VJ, Peterson AM, Manke AA, Patel DD, Ajmera MR
University of the Sciences, Philadelphia, PA, USA
OBJECTIVES: To evaluate an online freeware, cost-effectiveness calculator that gener-
ates and plots estimations related to the impact of medication compliance on life years
gained, drug expenditures, and total health care cost. METHODS: An online calcula-
tor and plotter were developed that estimates the impact of patient compliance on the 
cost-effectiveness of therapy. This model was based on a more complex compliance 
model description published by Hughes D. et al. The online data calculations were
compared with an MS Excel spreadsheet model. The cost effectiveness calculator is 
freely available through www.healthstrategy.com. Data inputs that can be modiﬁ ed 
include (for compliant and non-compliant separately): utility (QoL), annual drug
costs, annual non-drug costs, percent deaths per year, total number of study years, 
and number of initial patients. RESULTS: The online calculator runs on most personal
computer operating systems with javascript enabled browsers such as Internet
Explorer, Firefox, Opera, or Safari. For twenty different levels compliance (from 0 to
100 percent) this Internet tool outputs and plots results for: total QALYs, life years, 
total health care costs, non-drug expenditures and total health care expenditures. For 
100 patients over 5 years, the MS Excel spreadsheet data versus the online calculated 
values compared as follows for 50% compliance: QALYs (372 vs. 375), Life Years:(451
vs. 450), drug costs:($23,750 vs. $23,750), non-drug costs:($228,750 vs. $225,000), 
total health care costs:($252,500 vs. $248,750). CONCLUSIONS: With this online 
compliance and cost-effectiveness software, the user can enter their own data to cal-
culate and graph estimated QALYs, Life Years, drug costs, non-drug costs and total
health expenditures. This web-based calculator has potential beneﬁ t as a basic tool 
for students, health professionals, and decision-makers.
PMC16
EVALUATING AN ONLINE FREEWARE CALCULATOR AND
PLOTTER FOR POWER ANALYSIS AND SAMPLE SIZE ESTIMATION
FOR COST EFFECTIVENESS STUDIES
McGhan WF, Willey VJ, Peterson AM
University of the Sciences, Philadelphia, PA, USA
OBJECTIVES: To evaluate an online, freeware calculator that generates and plots
sample size estimations and power analyses for cost effectiveness studies. METHODS:
Online software was developed and results were compared with a published analytical 
formula for power analysis and sample size calculations for cost and effectiveness data. 
The web-based, cost effectiveness calculator formulas, data and evaluation were based
on published articles by Briggs A, Gray AM and Tambour M. The online calculator 
required data inputs include: probability of Type I and Type II error, standard devia-
tion of costs and effects, mean cost and effect differences, correlation between differ-
ences in cost and effects, as well as willingness to pay (WTP) for additional health
effects. This Internet tool outputs results for sample size in each study arm that would
be required versus WTP threshold ranges, and power versus sample size. RESULTS:
Compared to the published manuscripts for a power of 0.90 and effectiveness only, 
the online calculated sample size results were identical (N  536). For the published 
examples with correlation differences in effect and cost of minus 1.0, the estimated 
sample sizes based on WTP compared as follows: WTP  $7500:(1400 vs 1387), WTP 
 $10,000:(1150 vs 1096), WTP  $15,000:(850 vs 865), WTP  $20,000:(790 vs 
769), WTP  $30,000:(700 vs 682). The Briggs et al articles include additional results
and sensitivity analyses based on additional correlations and power, which have to be
run one at a time with the online software. CONCLUSIONS: With this online freeware 
calculator, the user can enter their own data to estimate sample size and power in
planned or published cost effectiveness studies. This web-based software has potential
beneﬁ t as a basic tool for students, health professionals, and decision makers.
PMC19
COST–EFFECTIVENESS OF PREVENTIVE CARE AND MEDICINES: DO
AGING DISEASES OFFSET SAVINGS FROM MORBIDITY REDUCTION?
Gandjour A
Rice University, Houston, TX, USA
OBJECTIVES: A major concern about the economic impact of preventive care
and medicines is that savings from avoiding morbidity may be more than offset 
by the costs of prolonging life, resulting in a net expenditure increase. The purpose
of this work is to examine this hypothesis. METHODS: A theoretical model is 
developed which determines the net outcome when savings from preventing morbidity 
are weighed against expenditures for added life years. The model is based on a single 
assumption, which is that costs and mortality are linearly correlated. This assumption 
holds for preventing the average disease because preventing all disease reduces 
mortality and costs by 100%. The model is validated based on long-term studies 
from the U.S. and Netherlands that model the economic impact of chronic-disease 
prevention. RESULTS: The model shows that for the average preventive measure 
savings from preventing morbidity are somewhat larger than expenditures in added 
life years. The ratio of savings to expenditures is approximately 1/(1 – relative reduc-
tion in all-cause mortality). The model is able to explain why some studies show 
that preventing chronic disease leads to savings while others do not. CONCLUSIONS:
This work provides new insight into the cost consequences of preventive care and
medicines. Results have implications for the economic evaluation of preventive 
medicines. For the average drug the long-term cost driver is not the additional life 
span, as expenditures during added life years roughly equal savings from morbidity 
reduction. Instead, increases in long-term costs are, on average, mainly driven by the 
medication itself.
PMC20
ESTIMATION OF HETEROGENOUS AVERAGE TREATMENT EFFECT
OF BIOLOGIC DMARDS– PANEL DATA CORRELATED RANDOM
COEFFICIENTS MODEL WITH POLYCHOTOMOUS ENDOGENOUS
TREATMENT
Kawatkar AA, Nichol MB
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To estimate the treatment effects of biologic disease modifying anti-
rheumatoid drugs (DMARDs) on quarterly total health care expenditure, while 
controlling endogeneity in treatment choice and allowing heterogeneity in treatment 
effects. The structural parameters, heterogeneous (ATE), and homogeneous (ATE1) 
average treatment effects were deﬁ ned as the impact of treatment on quarterly 
expenditure, if patients are randomly assigned to biologic DMARDs. METHODS:
Retrospective cohorts were constructed from California Medicaid paid claims between
January 1, 1999 to December 31, 2005. Non-overlapping quarters were created from 
pharmacy claims for biologic (adalimumab and etanercept) and standard (leﬂ uono-
mide, hydroxychloroquine and sulfasalazine) DMARDs. Final sample included 24504
episodes on 5510 patients. In the two-stage estimation, the treatment selection 
model was varied between multinomial and nested-logit, to avoid independence of 
irrelevant alternatives. The outcome equation was panel data ﬁ xed-effects correlated
random coefﬁ cients model (Wooldridge-2005), allowing heterogeneity in parameters.
